活动性或近期恶性肿瘤的炎症性肠病患者中生物制剂的安全性比较:多中心队列研究
该多中心回顾性队列研究比较了肿瘤坏死因子α拮抗剂与非TNF生物制剂在活动性癌症(队列A)或近期既往癌症(≤5年,队列B)的炎症性肠病患者中的安全性,主要结局分别为无进展生存期和无复发生存期。结果显示两组无进展生存期(HR 0.76,95%CI 0.25-2.30)和无复发生存期(HR 0.94,95%CI 0.24-3.77)均无显著差异,安全性相当。
要点
- 活动性癌症患者中,TNFα拮抗剂组55例中10例进展(发病率4.4/100人年),非TNF生物制剂组40例中9例进展(发病率10.4/100人年)。
- 近期既往癌症患者中,TNFα拮抗剂组78例中8例复发(发病率3.4/100人年),非TNF生物制剂组66例中5例复发(发病率3.7/100人年)。
- 两组无进展生存期(HR 0.76,95%CI 0.25-2.30)和无复发生存期(HR 0.94,95%CI 0.24-3.77)均无显著差异。
核心结论
- 在活动性或近期癌症的炎症性肠病患者中,TNFα拮抗剂与非TNF生物制剂具有可比的安全性。
- 生物制剂的选择应与肿瘤科医生协作,由炎症性肠病疾病严重程度决定。
研究设计与样本
- 多中心回顾性队列研究,纳入炎症性肠病合并活动性癌症(队列A)或近期既往癌症(诊断后≤5年,队列B)后接受TNFα拮抗剂或非TNF生物制剂治疗的患者。
- 队列A共125例(随访483.8人年),年龄54±15岁,75%为实体器官恶性肿瘤。
- 队列B共170例(随访513人年),年龄53±15岁,84%为实体器官恶性肿瘤,缓解持续时间19±19个月。
- 主要结局:队列A为无进展生存期,队列B为无复发生存期;采用倾向评分逆概率治疗加权比较安全性。
主要发现
- 队列A中,TNFα拮抗剂组55例中10例癌症进展(发病率4.4/100人年),非TNF生物制剂组40例中9例进展(发病率10.4/100人年)。
- 队列A中两组无进展生存期风险无差异(HR 0.76,95%CI 0.25-2.30)。
- 队列B中,TNFα拮抗剂组78例中8例癌症复发(发病率3.4/100人年),非TNF生物制剂组66例中5例复发(发病率3.7/100人年)。
- 队列B中两组无复发生存期风险相似(HR 0.94,95%CI 0.24-3.77)。
临床怎么用
- 作者认为,在活动性或近期癌症的炎症性肠病患者中,TNFα拮抗剂与非TNF生物制剂安全性相当。
- 作者建议,生物制剂的选择应与肿瘤科医生协作,由炎症性肠病疾病严重程度决定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Safety of biologic agents is a key consideration in patients with inflammatory bowel disease (IBD) and active or recent cancer. We compared the safety of tumor necrosis factor (TNF)-α antagonists vs non-TNF biologics in patients with IBD with active or recent cancer. METHODS: We conducted a multicenter retrospective cohort study of patients with IBD and either active cancer (cohort A) or recent prior cancer (within ≤5 years; cohort B) who were treated with TNFα antagonists or non-TNF biologics after their cancer diagnosis. Primary outcomes were progression-free survival (cohort A) or recurrence-free survival (cohort B). Safety was compared using inverse probability of treatment weighting with propensity scores. RESULTS: In cohort A, of 125 patients (483.8 person-years of follow-up evaluation) with active cancer (age, 54 ± 15 y, 75% solid-organ malignancy), 10 of 55 (incidence rate [IR] per 100 py, 4.4) and 9 of 40 (IR, 10.4) patients treated with TNFα antagonists and non-TNF biologics had cancer progression, respectively. There was no difference in the risk of progression-free survival between TNFα antagonists vs non-TNF biologics (hazard ratio, 0.76; 95% CI, 0.25-2.30). In cohort B, of 170 patients (513 person-years of follow-up evaluation) with recent prior cancer (age, 53 ± 15 y, 84% solid-organ malignancy; duration of remission, 19 ± 19 mo), 8 of 78 (IR, 3.4) and 5 of 66 (IR 3.7) patients treated with TNFα antagonists and non-TNF biologics had cancer recurrence, respectively. The risk of recurrence-free survival was similar between both groups (hazard ratio, 0.94; 95% CI, 0.24-3.77). CONCLUSIONS: In patients with IBD with active or recent cancer, TNFα antagonists and non-TNF biologics have comparable safety. The choice of biologic should be dictated by IBD disease severity in collaboration with an oncologist.
引用
- Holmer AK, Luo J, Russ KB, et al. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study. Clin Gastroenterol Hepatol. 2023. PMID: 36642291. doi:10.1016/j.cgh.2023.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。